Skip to main content

Table 6 Incremental net monetary benefit values and probabilities for each vaccination strategy at a willingness-to-pay threshold of $872 per DALY averted

From: Seasonal influenza vaccination in Kenya: an economic evaluation using dynamic transmission modelling

Strategy Mean INMB value in ‘000 s INMB 95% credible interval in ‘000 s Probability of highest INMB benefit Rank
Lower quantile Upper quantile
Strategy IA − 472 − 6201 10,054 4% 5
Strategy IB 3 − 5975 13,302 3% 1
Strategy IC − 217 − 6976 13,545 0% 3
Strategy ID − 3424 −10,351 9188 0% 8
Strategy IIA − 1293 −14,377 23,996 11% 7
Strategy IIB − 581 −13,854 28,726 7% 6
Strategy IIC − 387 −15,597 31,947 2% 4
Strategy IID − 7507 −22,440 20,834 0% 11
Strategy IIIA − 7077 −36,674 53,262 12% 10
Strategy IIIB − 7531 −35,320 44,647 12% 12
Strategy IIIC − 3633 −39,244 70,255 14% 9
Strategy IIID − 20,326 −54,467 42,876 0% 13
No vaccine 0 35% 2
  1. INMB incremental net monetary benefit. Strategies are vaccinating children 6–23 months (strategy I), 2–5 years (strategy II) and 6–14 years (strategy III) with either the Southern Hemisphere influenza vaccine (Strategy A) or Northern Hemisphere vaccine (Strategy B) or both (Strategy C: twice yearly 3-month vaccination periods, or Strategy D: year-round vaccination)